In Vivo CRO Market Size, Share and Trends 2024 to 2034

In Vivo CRO Market Size and Forecast 2024 to 2034

The global in vivo CRO market size is projected to be worth around USD 10.89 billion by 2034 from USD 4.99 billion in 2024, at a CAGR of 8.11% from 2024 to 2034. The North America in vivo CRO market size reached USD 2.36 billion in 2023. The rising demand for the clinical research outsourcing is driving the growth of the market.

In Vivo CRO Market Key Takeaways

• North America dominated the in vivo CRO market with the highest market share of 51% in 2023.
• Asia Pacific is expected to see a significant growth in the market during the forecast period.
• By model type, the rodent based segment has contributed more than 82% of market share in 2023.
• By model type, the non-rodent based segment is expected a significant growth in the market during anticipated period.
• By modality, the small molecules segment held the largest market share in 2023.
• By modality, large molecules segment is anticipated to increase its growth in the market during the predicted period.
• By GLP type, GLP toxicology segment dominated the market in 2023.
• By GLP type, the non GLP segment expected a significant growth in the market during the anticipated period.
• By indication, oncology segment dominated the market with largest share in 2023.
• By indication, CNS conditions segment is expected to capture the fastest growth over the predicted period.

U.S. In Vivo CRO Market Size and Growth 2024 to 2034

The U.S. in vivo CRO market size was exhibited at USD 1.77 billion in 2023 and is projected to be worth around USD 4.23 billion by 2034, poised to grow at a CAGR of 8.24% from 2024 to 2034.

North America dominated the in vivo CRO market with the largest market share in 2023. The growth of the market is attributed to the higher availability of the major pharmaceutical and biotechnological firms and the increasing investment in the innovations and discovery of the drugs are driving the growth of the market. Additionally, the rising demand for the discovery drugs and clinical studies for the formulation and the development of drugs for the treatment of rising number of chronic conditions are driving the growth of the in vivo CRO market in the region.

• The United States share is approximately 8500 increased than the combined 10 leading countries. There are five leading countries are dominating in terms of clinical research in which the United States with the 1,254 (35.7%), China with 685.03 (19.5%), United Kingdom with 260.72 (7.4%), Germany with 211.24 (6.0%), Japan with 112.09 (3.2%), and other countries 993.12 (28.2%). 
• The leading ranked the highest in the clinical infectious diseases including the United States with 311.79 (46.3%), Canada with the 34.80 (5.2%), United Kingdom 29.34 (4.4%), France 23.03 (3.4%), and South Korea 22.05 (3.2%).

Asia Pacific is expected a significant growth in the market during the forecast period. The growth of the market is expected to rise due to the increasing population and the rising development in the pharmaceutical and biotechnology sector.  The increasing regional population and the increasing prevalence of the several disease in the population is driving the demand for the drug development that boost the clinical research cases in the pharmaceutical and biotech laboratories that boosts the outsourcing of the clinical trials that drives the growth of the in vivo CRO market.

• The Indian pharmaceutical industry is anticipated to reach US$ 65 billion by 2024, US$130 billion by 2030, and US$450 billion by 2047.
• There are about 20% of the generic medicine for the global export met by India. India is in the top 12 countries for the biotechnology worldwide and the 3rd largest country in terms of biotechnology in Asia Pacific.

Market Overview

The contract research organization is the independent organization or body that help in the clinical trial or medical studies for the drug discovery. The organization works in providing research services to the pharmaceutical, biotechnology, medical devices, government agencies, academic institutions, and foundation. The contract research provides the number of services to the various healthcare institutes such as it offers clinical trial management, preclinical research, biostatics, data management, regularity affairs. There are three major types of CROs such as full-service CROs, functional services provider (FSPs), and specialty CROs. The rising demand for the drug discovery are driving the growth of the in vivo CRO market.

How AI can impact the in vivo CRO Industry?

The integration of the artificial intelligence is revolutionizing the healthcare, pharmaceutical, and biotechnology industry. Artificial intelligence improves the overall efficiency, accuracy of the services. The rising integration of AI into the clinical research driving the new opportunities in the drug discovery and development process. The adaptation of AI in CRO is drives the operations in the clinical research it increased the data quality, rapid trial completion, and enhanced patient safety. Data analysis by the artificial intelligence is helps in detecting anomalies and outliners that affect the clinical trial. AI could lead data reliability and integrity. AI streamline trial operations to increase the patient outcomes and disease and disease detection. Artificial intelligence play an important role in the advancement in the medical knowledge and improves the drug discovery process.

• In July 2024, Fortrea introduces the research and development program vision to create artificial intelligence enabled clinical trial technologies for making safer, speedier, and more efficient studies.

In Vivo CRO Market Growth Factors

• The rising development in the healthcare, pharamecutical, and biotechnolgy sector and the increasing population that drives the demand for the better healthcare system that drives the growth of the in vivo CRO market.
• The increasing prevalence of the chronic diseases in the population and the rising demand for the efficient treatment procedures are boosting the CROs by the pharmaceutical firms that drives the growth of market.
• The increased in the outsourcing the clinical trials drug development, and localized services are boosting the growth of the CROs. Additionally, the increasing presence of the CROs in the several region for meeting the growing demand for the patients with the several health conditions are boosting the growth of the in vivo CRO market.

Market Scope

Market Dynamics

Driver

Rising acceptance of the CRO in the clinical trial

The clinical development is the challenging operations in the healthcare sector. The CRO plays an important role in the improving the clinical and pharmaceutical development, it ensure the ethical and safer clinical trial that necessary for the development of the innovative drug, treatment procedures, and medical devices that helps in better outcome of millions of patients. With the changing regularity standards and rising demand of the pharmaceutical and biotechnology companies, there are several CRO companies enhanced their services including AI, decentralized trials, various innovatory services that helps in enhancing the patient recruitment.

Top CRO Companies that offer clinical trials in 2024

• IQVIA
• ICON plc
• Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
• TFS HealthScience
• Charles River Laboratories International, Inc.
• Laboratory Corporation of America
• Syneos Health®
• Parexel International Corporation
• WuXi AppTec, Inc
• Clinipace (Caidya)

Restraint

Several limitation are associated with the CROs

There are several limitation in association with the CROs including limitation in control over research, communication challenge, and lower familiarities with the project, intellectual property ownership concern, and several other limitations are restraining the growth of the in vivo CRO market.

Opportunity

Technological advancements in the CROs

The technological adoption in the CRO is driving the revolution in the clinical trial and drug discovery. The technological advancements drives the opportunities in improving services in the CROs. The integration of the tech-enabled patient-recruitment and management, decentralized and remote trials, wearable technology, and biosimulation. Additionally, the rising investment by the public and private firm in the clinical trial and drug discovery is driving the growth of the in vivo CRO market.

Model Type Insights

The rodent-based segment dominated the in vivo CRO market with the largest share in 2023. The segment's growth is owing to the higher use of rodents as the model for research in several clinical trials for drug and treatment innovations. It is highly used in the medical study and trials. Rodents are extensively used in medical research due to their similar behaviors, genetics, and biology to humans. Rodents have almost the same immune system as humans. They might experience the same disease and similar types of organs and bodily systems as humans. It is stated that around 95% of the gene codes of rodents are identical to those of humans. Thus, they are the ideal model for clinical trials for human diseases. Rodents are efficiently used in clinical trials for cardiovascular disease. Therefore, the higher use of rodent models for clinical trials and medical studies drives the demand for the segment.

The non-rodent-based segment is expected to have significant growth in the market during an anticipated period. The rising use of the non-rodent segment for offering research and several benefits in terms of drug development, homology to humans, body weight, metabolism, organ structure, etc.

Modality Insights

The small molecules segment held the largest market share in 2023. Small molecule plays an essential role in various medical breakthroughs, meeting medical demands; it is vital as the chemical probe in biomedical research and understanding disease biology. Small molecule drug discovery develops the drugs used for particular targets in the body, like receptors, enzymes, and ion channels. It helps maintain their activity for the treatment or prevention of various diseases. It is used in different stages, including validation, target identification, lead optimization, and hit identification.

• For Instance, In December 2023, Deep Apple Therapeutics announced $52 million in series fund from Apple Tree Partners for the development of small molecule drugs for the metabolic disease.

The large molecules segment is anticipated to increase its growth in the market during the predicted period. The increasing development of large-molecule drug products due to their higher efficiency in disease treatment has improved the large-molecule bioanalysis CROs. The large molecule drug products, including protein, peptides, antibody-drug conjugates, and monoclonal antibodies, effectively help treat and prevent several disease indications. The most common large molecule bioanalytical studies are pharmacokinetic (PK) studies, immunogenicity testing, pharmacodynamics (PD) studies, and biomarker assays.

GLP Type Insights

The GLP toxicology segment dominated the in vivo CRO market in 2023. The GLP toxicology plays an important role in the any type of the medical study or the clinical trials. The GLP toxicology studies helps in identifying the toxicological effects on the dosage that lower than in use for human clinical trials. The GLP toxicology majorly involves in the model organisms like rodents and offer valuable insights about the toxicity of the drug on the various organs and biological system.

The non-GLP segment expected a significant growth in the market during the anticipated period. The non-GLP segment is the drug development procedure that involves in the clinical or medical studies. These clinical studies are comply on the GLP regulation. The non-GLP toxicology studies can be comply on the various drug development and detection process that boosts the growth of the market.

Indication Insights

The oncology segment dominated the market with largest share in 2023. The increasing prevalence of the cancer all around the world due to the changing lifestyle habits, and other issues that contributing in the demand for the drug development for the treatment of the disease. There are ongoing investment by the private and public firm on the development of the drug or the treatment procedures that drives the adoption of the CROs for the clinical trial and medical studies in the development of the drug for the oncology. Thus, the increasing number of patients with the various types of cancer that drives the growth of the segment.

• As per the report of The International Agency for Research on Cancer (IARC) in 2022, the cancer is the cause for the 9.7 million deaths in 2022, in which 1 in 9 and 1 in 12 men and women is expected to die from cancer respectively.

The CNS conditions segment is expected to capture the fastest growth over the predicted period. The increasing cases of the CNS diseases including Huntington’s disease (HD), Epilepsy, Parkinson’s disease (PD), stroke, and Traumatic Brain Injury (TBI). CROs provides the informative insights, understanding for conducting preclinical investigation and specialized services. The rising demand for drug discovery for the various types of the CNS conditions is contributing in the growth of the market.

In Vivo CRO Markets Top 15 Companies

• IQVIA Inc.
• Crown Bioscience
• Taconic Biosciences, Inc.
• PsychoGenics Inc.
• Evotec
• Janvier Labs
• Biocytogen Boston Corp
• GemPharmatech
• Charles River Laboratories
• Icon Plc
• Labcorp Drug Development
• Parexel International Corporation
• SMO Clinical Research (I) Pvt Ltd.
• Comp14
• Comp15

Recent Developments

• In November 2023, Crown Bioscience, a leading contract research organization (CRO) and partner firm JSR Life Sciences Company launched the OrganoidXploreTM, a revolutionary service offering, organoid panel screening platform consists of clinically relevant output at record speed, and robust, reproducible, that helps in fueling preclinical oncology drug discovery by researchers.
• In December 2023, Pharmaron’s collaboration with the Xceleron for the future support for the early preclinical discovery and clinical development with the extended radiolabeled sciences capabilities.
• In March 2024, ND-based Agathos Biologics, ‘Fargo’ introduces the recombinant adeno-associated virus (rAAV) production service with the use of proprietary cell line, AE1-BHK. It records the first sale rAAV to a CRO, Genovac, and CMO.

Segments Covered in the Report

By Model Type

• Rodent Based
  • Rat Models
  • Mice Models
  • Others
• Non-Rodent Based

By Modality

• Small Molecules
• Large Molecules
  • Cell & Gene Therapy
    • CAR T-cell Therapies
    • CAR-NK Cell Therapy
    • TCR-T Cell Therapy
    • Other (Includes- TCR-NK, CARM, and TAC-T)
  • RNA Therapy
  • Others

By Indication

• Oncology
  • Blood Cancer
  • Solid Tumor
    • Syngeneic Model
    • Patient Derived Xenograft
    • Xenograft
  • Others
• CNS Conditions
  • Epilepsy
  • Parkinson's disease
  • Huntington's Disease
  • Stroke
  • Muscular Dystrophy
  • Alzheimer’s Disease
  • Traumatic Brain Injury
  • Amyotrophic Lateral Sclerosis (ALS)
  • Spinal Muscular Atrophy
  • Muscle Regeneration
  • Other Neurodevelopment Disorders
• Diabetes
• Obesity
• Pain Management
  • Chronic Pain
  • Acute Pain
• Autoimmune/Inflammation Conditions
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome
  • Others
• Others

By GLP Type

• GLP Toxicology
• Non-GLP

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa